SAGE — Sage Therapeutics Cashflow Statement
0.000.00%
- $457.13m
- $33.28m
- $41.24m
- 31
- 20
- 39
- 19
Annual cashflow statement for Sage Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 606 | -458 | -533 | -541 | -401 |
Depreciation | |||||
Non-Cash Items | 95.3 | 94 | 66 | 66.9 | 47.7 |
Other Non-Cash Items | |||||
Changes in Working Capital | -39.7 | -18.5 | 5.67 | -67.4 | 84.8 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | 664 | -378 | -460 | -541 | -267 |
Capital Expenditures | -0.345 | -0.372 | -0.937 | -0.553 | 0 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 443 | -1,002 | 326 | 443 | 267 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 443 | -1,002 | 325 | 443 | 267 |
Financing Cash Flow Items | — | -1.39 | -0.043 | -0.903 | -0.52 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 427 | 13.3 | 3.07 | 6.03 | 10.7 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1,534 | -1,367 | -132 | -91.6 | 10.1 |